KZIA

NASDAQ open

Kazia Therapeutics

4.80 USD
▼-0.57-10.71%
盘后 8.75 0.00%
2026-11-20
市值
$67.42M
市盈率
—
EPS
-3.70
股息率
—
52 周区间
4.80 – 17.40
成交量
268.01K
Beta
2.36
目标价
27.68
52W 低 4.8052W 高 17.40
价格走势

公司简介

Kazia Therapeutics Limited, through its subsidiaries, operates as an oncology-focused biotechnology company in Israel. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in ...